Bioasis Announces Shares for Debt Transaction
February 10, 2021 19:02 ET
|
Bioasis Technologies Inc.
NEW HAVEN, Conn., Feb. 10, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™...
Bioasis Announces $200,000 Non-Brokered Private Placement
January 29, 2021 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 29, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3 ™...
Bioasis Announces Filing of Its Quarter and Financial Statements and MD&A for the Period Ending November 30, 2020
January 27, 2021 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 27, 2021 (GLOBE NEWSWIRE) -- Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Stock Option Grant
January 22, 2021 09:19 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 22, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a pre-clinical, research-stage biopharmaceutical company developing its proprietary xB3™...
Bioasis to Present at Upcoming Industry Conferences
January 04, 2021 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Jan. 04, 2021 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. – Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Annual General Meeting Results
December 10, 2020 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Dec. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Annual General Meeting Details
November 10, 2020 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Sale of Royalty Interest in Lysosomal Storage Disorder Enzymes Being Developed Under the Chiesi Group–Bioasis Strategic Alliance to XOMA Corporation
November 03, 2020 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Nov. 03, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC–Bioasis Technologies Inc. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a pre-clinical, research-stage...
Bioasis Announces Filing of Its Quarterly Financial Statements and MD&A for the Period Ending August 31, 2020
October 29, 2020 16:58 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Oct. 29, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI.V; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...
Bioasis Announces Analyst Coverage Initiated by Zacks Investment Research
October 22, 2020 16:05 ET
|
Bioasis Technologies Inc.
GUILFORD, Conn., Oct. 22, 2020 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSXV:BTI; OTCQB:BIOAF), (the “Company” or “Bioasis”), a pre-clinical, research-stage biopharmaceutical company...